Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Assets (2016 - 2025)

Historic Assets for Heron Therapeutics (HRTX) over the last 14 years, with Q3 2025 value amounting to $249.0 million.

  • Heron Therapeutics' Assets rose 1276.08% to $249.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $249.0 million, marking a year-over-year increase of 1276.08%. This contributed to the annual value of $233.1 million for FY2024, which is 478.23% up from last year.
  • As of Q3 2025, Heron Therapeutics' Assets stood at $249.0 million, which was up 1276.08% from $232.1 million recorded in Q2 2025.
  • In the past 5 years, Heron Therapeutics' Assets ranged from a high of $404.2 million in Q2 2021 and a low of $201.2 million during Q2 2023
  • For the 5-year period, Heron Therapeutics' Assets averaged around $257.6 million, with its median value being $235.8 million (2025).
  • Its Assets has fluctuated over the past 5 years, first crashed by 3965.0% in 2022, then skyrocketed by 1276.08% in 2025.
  • Heron Therapeutics' Assets (Quarter) stood at $305.7 million in 2021, then fell by 17.91% to $251.0 million in 2022, then fell by 11.33% to $222.5 million in 2023, then grew by 4.78% to $233.1 million in 2024, then increased by 6.78% to $249.0 million in 2025.
  • Its Assets was $249.0 million in Q3 2025, compared to $232.1 million in Q2 2025 and $235.8 million in Q1 2025.